Sarborg

What Sarborg does

Sarborg Limited is a privately held agentic AI company that develops and licenses a proprietary Signature Intelligence platform for pharmaceutical, biotech, agrichemical, veterinary, bacterial, and industrial customers. Its core technology, the Signature Agent, encodes biological, chemical, and industrial signatures into binary matrices and matches them against six proprietary databases containing over 15,000 curated signatures. The platform operates without large language models, using deterministic signature-matching logic that returns ranked indications in under five minutes. A multi-agent evaluation layer (Deal-Breaker, Patient, Commercial, R&D, IP Landscape, and Solid-Form IP agents) produces red/amber/green verdicts and Target Product Profiles for asset diligence.

The business model is centered on technology licensing, strategic partnerships, and collaboration agreements with pharmaceutical and biotech counterparties. Sarborg also holds an owned portfolio of pharmaceutical solid-form and cocrystal patents (THCA, CBDA, CBG, CBDA Choline, two Cystic Fibrosis assets) and an acquired cannabinoid portfolio from Manoira Corporation, generating potential revenue through licensing or sale. Go-to-market is direct enterprise sales through custom engagement arrangements; pricing is not publicly disclosed. The company's named commercial customer is Conduit Pharmaceuticals, with a strategic equity and collaboration relationship held by CDT Equity Inc., which acquired a 20% stake for $115 million in February 2026. Sarborg launched SarborgQ, a wholly-owned quantum computing subsidiary, in June 2026 to extend the platform toward mechanistic architecture understanding of biological systems, funded at a fully diluted valuation of approximately $638.3 million.

Name

Sarborg

Legal name

Sarborg Limited

Website

https://sarborg.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Sarborg is a privately held agentic AI company that builds deterministic, non-LLM signature-matching software for pharmaceutical, biotech, agrichemical, veterinary, and industrial customers. It licenses proprietary Signature Agent technology and proprietary signature databases to accelerate drug repurposing, asset evaluation, and indication discovery.

Ownership category

akta.pro rank

Headquarters

HQ city

Grand Cayman

HQ country

Cayman Islands

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

1. Technology Licensing: Licensing of proprietary AI signature intelligence technology and agent platforms to pharmaceutical, biotech, and agrichemical companies for drug discovery and asset evaluation.
2. Partnership and Collaboration Agreements: Strategic partnerships with pharma and biotech companies for signature campaign analysis at scale, potentially generating upfront payments, milestones, and royalties.
3. Pharmaceutical IP Portfolio: Revenue from owned pharmaceutical patents including solid-form and cocrystal assets (THCA, CBDA, CBG, CBDA Choline, Cystic Fibrosis assets) through licensing or sale.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Sarborg develops an agentic AI Signature Intelligence platform that decodes biological, chemical, and industrial signatures into a universal data language, enabling drug repurposing, candidate evaluation, and novel indication discovery. The platform runs deterministic signature-matching logic (no LLMs) against six proprietary databases containing over 15,000 curated signatures, returning ranked indications in under five minutes. Sarborg licenses the platform, databases, and its Multi-Agent Evaluation System to pharmaceutical, biotech, agrichemical, and academic partners, and also owns a portfolio of pharmaceutical solid-form and cocrystal patents surfaced through the engine.

Product overview

Sarborg is an agentic AI intelligence business operating as a platform-plus-modules architecture. The core is the Signature Agent—an autonomous, deterministic matching system that processes biological, chemical, and industrial signatures in under five minutes without LLMs. Built on six proprietary signature databases totaling over 15,000 curated signatures, the platform includes the Multi-Agent System for comprehensive asset evaluation (Deal-Breaker, Landscape, IP, and Solid-Form agents). The PRISM Agrichemical Agent extends capabilities into agricultural biotechnology, while SarborgQ represents a quantum computing division advancing toward mechanistic understanding and designed solutions. The company also maintains a pharmaceutical patent portfolio of solid-form and cocrystal assets identified through its signature network. All components share the foundational signature-matching engine but serve distinct analytical purposes across pharmaceuticals, rare diseases, agrichemicals, bacteria, veterinary, and industrial sectors.

Differentiator

Problem solved

Functional benefit

Brands

• SarborgQ: Quantum computing division applying quantum computing to the Signature Intelligence platform for mechanistic understanding of biological systems and designing new biological and chemical solutions.

Products and services

• Signature Agent Autonomous agentic AI product that ingests a raw drug signature (.gmt file), encodes it into a binary matrix, routes it against one of Sarborg's proprietary reference databases, performs connectivity mapping and pathway enrichment, and returns a ranked indication report in under five minutes. Sold/licensed to pharmaceutical, biotech, agrichemical, and academic partners.
• Multi-Agent Evaluation System Standalone multi-agent product comprising Deal-Breaker, Patient, Commercial, R&D, IP Landscape, and Solid-Form IP agents that evaluate pharmaceutical and biotech assets and return red/amber/green verdicts compiled into a Target Product Profile. Targeted at pharma business development and asset diligence teams.
• PRISM Agrichemical Agent Cross-species connectivity mapping framework (PRISM) delivered as an agent product for the agrichemical sector, enabling mode-of-action mapping over agricultural compounds and translational agriculture use cases.
• SarborgQ Quantum computing product/division applying quantum-native algorithms to mechanistic understanding of biological systems and to first-principles design of new biological and chemical solutions, including quantum-assisted coformer selection for solid-state drug forms.
• Signature Databases Six proprietary curated signature databases — Disease (~1,600), Rare Disease (~1,700), Agrichemical (~4,500), Bacterial (~7,000), Veterinary (~300), and Sarborg Drug Signatures (~15) — licensed to pharma, biotech, agrichemical, and academic partners for use with the Signature Agent and PRISM agent.
• Pharmaceutical Asset Portfolio Owned portfolio of pharmaceutical solid-form and cocrystal patent assets — THCA, CBDA, CBG, CBDA Choline, and two Cystic Fibrosis substance-of-matter compounds — made available for licensing or sale to pharma and biotech partners.

Quantifiable outcome

• Under 5 minutes from raw gene input to ranked indication output
• +2 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Manoira CorporationminorOthers · 28 April 2026Sarborg completed acquisition of a portfolio of next-generation patented cannabinoid solid-form assets from Manoira Corporation.
• Conduit PharmaceuticalscoreStrategic or Co-development Partner · 27 August 2025Strategic collaboration initiated December 2024 to integrate AI and cybernetics into drug development operations. Aims to streamline drug repurposing, accelerate discovery, optimize solid-form identification, and enhance clinical trial monitoring. Expected to shorten development timelines, reduce costs, and improve predictability for Conduit assets including AZD1656, AZD5904, and CDT1656.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Emerging players

• Owkin: AI/ML platform company focused on biomedical research and drug discovery with federated learning across healthcare institutions. Comparable to Sarborg in serving pharma customers with proprietary AI architecture and cross-domain biological intelligence.
• Iambic Therapeutics: AI-driven drug discovery company combining physics-based modeling with generative AI for small molecule design. Comparable to Sarborg's signature/connectivity-mapping approach in pursuing non-LLM, deterministic architectures for drug discovery.

Direct peers

• InSilico Medicine: AI-driven biotech operating end-to-end drug discovery platforms including target identification and generative chemistry. Comparable to Sarborg in offering an integrated AI pharma platform with multi-vertical ambitions and partnered discovery.
• Insitro: Machine learning-driven drug discovery company combining data generation and predictive models to advance therapeutics. Comparable to Sarborg's positioning of proprietary data and ML architecture as a moat for asset evaluation and pipeline generation.
• Benevolent AI: AI drug discovery company combining biomedical knowledge graphs with machine learning to identify new drug targets and indications. Comparable to Sarborg's emphasis on indication discovery, repurposing, and ranked-output decision support for pharma.
• Exscientia: AI-driven pharma company using computational platforms to accelerate drug design and partnered discovery programs. Comparable to Sarborg in offering a software-plus-collaborations model that targets pharma repurposing, candidate triage, and indication expansion.
• Atomwise: AI-driven small molecule discovery company using structure-based design and proprietary models to identify drug candidates. Comparable to Sarborg in pursuing indication discovery and pharma partnerships with a differentiated AI architecture.
• Schrödinger, Inc. Public computational chemistry and materials science platform serving pharma and industrial customers with physics-based simulation and AI. Comparable to Sarborg in selling a deterministic computational platform (vs. LLM-based) into pharma drug discovery workflows.
• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Directly comparable to Sarborg in using AI to compress pharma R&D timelines and pursue drug repurposing and indication discovery.

Broad incumbents

• Isomorphic Labs: Alphabet subsidiary building an AI drug discovery platform derived from DeepMind's protein-structure work. Comparable to Sarborg as a well-capitalized AI pharma platform with ambitions to mechanistically design biology — and a potential competitor for SarborgQ's quantum-mechanistic narrative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sarborg